• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

MCL Therapy Selection and Sequencing

Opinion
Video

Panelists discuss the treatment- and patient-specific factors considered when determining induction therapy for treatment-naive patients with mantle cell lymphoma (MCL), including the decision between aggressive and less aggressive approaches, and how prior therapy exposure influences subsequent treatment sequencing for MCL.

  1. What treatment- and patient-specific factors do you consider when determining induction therapy for a treatment-naive patient with MCL (eg, aggressive vs less aggressive)?
  2. How do you sequence therapies for patients with MCL and how does prior therapy exposure influence your subsequent choice of treatments?
Related Videos
4 experts are featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
5 experts are featured in this series
4 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.